Centre Hospitalier Universitaire de Saint-Étienne

Running trials

• Not yet recruiting

  Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis

  NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source

• Not yet recruiting

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source

• Not yet recruiting

  Analysis of histological risk factors and biomarkers in paediatric retinoblastoma

  2024-515962-15-00· Phase 2· Institut Curie· Source

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Impact of Fatty Stimuli on Cerebral Activity in Anorexia Nervosa: a Multi-sensory Approach

  NCT07344831· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

  NCT06390436· Phase 4· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial

  NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Institut Curie· Source

• Not yet recruiting

  Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

  NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Study to assess the safety, tolerability, and effects of vortosiran in two groups: participants who previously had a blood clot and completed initial blood-thinner treatment, and participants with cancer who are at high risk of blood clots

  2026-525479-15-00· Phase 2· Ribocure Pharmaceuticals AB· Source

• Not yet recruiting

  Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

  NCT07644377· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)

  NCT07782112· Phase 3· Ente Ospedaliero Cantonale, Bellinzona· Source

• Not yet recruiting

  Impact of Continuous Positive Airway Pressure Therapy on Bilateral Local Hippocampal Gray Matter Volume in Elderly Patients With Obstructive Sleep Apnea - Study BBBSAS

  NCT07882433· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  Multiparametric MRI Assessment of Atrial Heart Disease as a Predictor of Atrial Fibrillation After Myocardial Revascularization Surgery

  NCT04657835· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

  NCT07152184· Phase 2· University Hospital, Strasbourg, France· Source

• Not yet recruiting

  Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

  NCT07717450· Phase 3· UNICANCER· Source

• Recruiting

  ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY

  NCT07545512· University Hospital, Clermont-Ferrand· Source

• Recruiting

  Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.

  2026-526775-27-00· Phase 2· Laboratoires Kol· Source

• Not yet recruiting

  Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

  NCT07151586· Phase 2· UNICANCER· Source

• Not yet recruiting

  Association Between Chronic Kidney Disease Stage and Circulating FGF23 Cleavage Intensity in Patients With Chronic Kidney Disease

  NCT07676526· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2

  2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source

• Not yet recruiting

  Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

  NCT07624799· Phase 2· French Innovative Leukemia Organisation· Source

• Not yet recruiting

  OBINUSS - A trial to evaluate a new drug in systemic sclerosis: obinutuzumab.

  2025-524003-68-00· Phase 2· Assistance Publique Hopitaux De Paris· Source

• Recruiting

  A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

  NCT07737743· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Not yet recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

  NCT07760818· Phase 2· argenx· Source

• Recruiting

  Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

  2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07481981· Phase 3· Insmed Incorporated· Source

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

  2024-519753-11-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Recruiting

  Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease

  NCT07632755· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)

  NCT07132164· University Hospital, Brest· Source

• Recruiting

  Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

  NCT07638553· Phase 3· Centre Hospitalier Universitaire de Nīmes· Source

• Recruiting

  Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study

  NCT07616687· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  Genotype/Phenotype Correlation of MORC2 Mutations

  NCT07038239· Hospices Civils de Lyon· Source

• Recruiting

  French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls

  NCT07881016· Fondation FondaMental· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

  NCT06494878· Phase 3· University of Calgary· Source

• Recruiting

  Insole Optimization for Rheumatoid Arthritis Patients

  NCT07321340· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis

  NCT07543679· Centre Hospitalier Universitaire de Saint Etienne· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  Impact of Endotest on Patients' Quality of Life: a Cohort Study

  NCT07560852· ZIWIG· Source

Showing 50 of 352.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers22 recruiting
• Crohn's disease15 recruiting
• Acute myeloid leukaemia12 recruiting
• Deep vein thrombosis and pulmonary embolism11 recruiting
• High blood pressure11 recruiting
• Ulcerative colitis11 recruiting
• Ovarian cancer9 recruiting
• Prostate cancer9 recruiting
• Colorectal cancer8 recruiting
• Metastatic breast cancer8 recruiting
• Multiple myeloma8 recruiting
• Pancreatic cancer8 recruiting
• Schizophrenia8 recruiting
• Sjögren's disease8 recruiting
• Kidney cancer7 recruiting
• Pulmonary arterial hypertension7 recruiting
• Rheumatoid arthritis7 recruiting
• Lung cancer6 recruiting
• Stroke6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Chronic kidney disease5 recruiting
• Sarcoma5 recruiting
• Alzheimer disease4 recruiting
• Bladder cancer4 recruiting
• Head and neck cancer4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Chronic myeloid leukaemia3 recruiting
• Coronary artery disease3 recruiting
• Depression3 recruiting
• Endometrial cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Myelodysplastic syndromes3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Osteoporosis3 recruiting
• Psoriasis3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Triple-negative breast cancer3 recruiting
• Ankylosing spondylitis2 recruiting
• Atrial fibrillation2 recruiting
• Brain aneurysm2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Endometriosis2 recruiting
• Glioblastoma2 recruiting
• Lupus (SLE)2 recruiting
• Neuroendocrine tumours2 recruiting
• Obstructive sleep apnoea2 recruiting
• Osteoarthritis2 recruiting
• Psoriatic arthritis2 recruiting
• Antiphospholipid syndrome1 recruiting
• Aortic aneurysm1 recruiting
• Aplastic anaemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Autism1 recruiting
• Bipolar disorder1 recruiting
• Cervical cancer1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• COPD1 recruiting
• Cytomegalovirus infection1 recruiting
• Diabetic neuropathy1 recruiting
• Down syndrome1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Giant cell arteritis1 recruiting
• Gout1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• Hidradenitis suppurativa1 recruiting
• HIV1 recruiting
• IgA nephropathy1 recruiting
• Iron deficiency anaemia1 recruiting
• Keratoconus1 recruiting
• Lyme disease1 recruiting
• Macular degeneration1 recruiting
• Nephrotic syndrome1 recruiting
• Polymyalgia rheumatica1 recruiting
• Sarcoidosis1 recruiting
• Type 1 diabetes1 recruiting
• Ventricular tachycardia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· Phase 3· Genmab· Source

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Recruiting

  Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

  NCT07286058· Phase 3· Takeda· Source

• Completed

  An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489

  2025-521155-23-00· Phase 2· Pfizer Inc.· Source

• Completed

  PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.

  2024-519258-35-00· Phase 2· Fondation Franc.Cancerologie Digestive· Source

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Recruiting

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· Phase 2· Tyra Biosciences, Inc· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

  NCT06671496· Phase 3· Takeda· Source

• Completed

  Assessing Transition Practices for Children With Disabilities: Pathways to a Successful Adulthood

  NCT07706517· Centre Hospitalier Universitaire de Saint Etienne· Source

• Active, not recruiting

  A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

  NCT06614192· Phase 2· AbbVie· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Source

• Completed

  PASSPORT

  NCT06274294· Phase 3· Centre Medico Chirurgical Ambroise Pare Hartmann· Source

• Completed

  A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

  2023-508992-35-00· Phase 2· Janssen Cilag International· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Completed

  Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution

  NCT06379880· Centre Paul Strauss· Source

• Completed

  Social Egg Freezing: Will Health Professionals Offer it ?

  NCT06529224· Centre Hospitalier Universitaire de Saint Etienne· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

• Completed

  A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

  NCT05975905· Phase 2· Keros Therapeutics Inc.· Source

• Completed

  Phosphoproteomic Profile of Children With Down Syndrome

  NCT06279208· Perha Pharmaceuticals· Source

• Completed

  A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006)

  2023-505520-61-00· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  Gait Profile Score in Children With Cerebral Palsy (CP): Influence of the CP Type, Treatment With Botulinum Injection and Multilevel Surgery

  NCT06505499· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  Customization of Cardiac Readaptation Based on Force-velocity Profile and Heart Rate Variability

  NCT06107452· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  Validation of a Remediation Method for Memory Disorders Using Motor and Emotional Encoding in Patients With Alzheimer's Disease

  NCT06105047· Centre Hospitalier Universitaire de Saint Etienne· Source

• Withdrawn

  Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer

  NCT04835987· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  Evaluating of the Impact of a Connected and Non-intrusive Device in Improving the Screening of Sleep Apnea Syndrome and the Addressing of Potentially Pathological Patients in Hospital Environment

  NCT06141967· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· AstraZeneca· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Terminated

  Food Intake and IgA Microbiota in Anorexia Nervosa

  NCT05842343· Centre Hospitalier Universitaire de Saint Etienne· Source

• Terminated

  The Role of Platelet TLRs in Platelet Activation During VTE

  NCT06257290· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Withdrawn

  Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects

  NCT03660722· Centre Hospitalier Universitaire de Saint Etienne· Source

• Terminated

  A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

  NCT05838742· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Amgen Inc.· Source

• Completed

  Pre-therapeutic Validation of the Virtual Reality-based Exposure Scenario for CBT "ReVBED" for the Induction of Food Craving in Patients With Bulimia and Binge Eating Disorder (BED)

  NCT05385653· Centre Hospitalier Universitaire de Saint Etienne· Source

• Completed

  Multicentric Evaluation of the True Negative Predictive Value of Multiparametric MRI for the Detection of Prostate Cancer Using Cystoprostatectomy Specimen as Reference

  NCT03960112· Institut Paoli-Calmettes· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures.

  NCT06067971· University Hospital, Clermont-Ferrand· Source

• Completed

  Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1

  2022-500905-42-00· Phase 1· University Hospital Grenoble· Source

• Completed

  Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

  NCT05570006· Phase 2· AbbVie· Source

• Completed

  Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

  NCT05665348· Phase 2/3· Federation Francophone de Cancerologie Digestive· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Recruiting

  Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis

  NCT04789850· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

  NCT05628233· Phase 2· Sensorion· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT05620823· Phase 3· Incyte Corporation· Source

Showing 50 of 126.

Conditions

Diseases this institution publishes on or runs trials for.

• Deep vein thrombosis and pulmonary embolism45 works · 20 trials